Close Menu

Philips

As part of the deal, scientists from Philips' Intellispace Genomics development team will relocate to NYMC's biotechnology incubator in Westchester County.

Philips plans to offer the software as a module in its IntelliSpace Genomics platform, which is used for integrating and analyzing genomic and phenotypic data.

One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.

The company is currently testing two versions of the software, one for clinical and one for research use, in an early-access program.

Title: Method of and system for applying blocking material to assay substrates.
Patent Number: 8,685,486
Filed: Aug. 10, 2011

NEW YORK (GenomeWeb News) – Biocartis today announced it is developing a workflow for extracting, amplifying, and detecting tumor DNA on its diagnostic platforms in collaboration with the Wellcome Trust Sanger Institute and Philips Research.

Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.

In addition, Argene will provide BioMérieux with a portfolio of molecular tests for diagnosing infectious diseases in transplant and other immunocompromised patients.

The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.